Prevalence of JAK2 V617F, CALR, and MPL W515L Gene Mutations in Patients with Essential Thrombocythemia in Kurdistan Region of Iraq

키워드

참고문헌 (30)

1. 이교관, "A Case of Post-Essential Thrombocythemia Myelofibrosis with Severe Osteosclerosis", Annals of Laboratory Medicine, 30(2), pp.122~125 (2010), 대한진단검사의학회
2. Kaushansky K, "On the molecular origins of the chronic myelo-proliferative disorders : it all makes sense", Blood, 105, pp.4187~4190 (2005)[DOI]
3. Ma W, "Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias", J Mol Diagn, 11, pp.49~53 (2009)[DOI]
4. Baxter EJ, "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders", Lancet, 365, pp.1054~1061 (2005)[DOI]
5. Antonioli E, "Clinical implications of the JAK2 V617F muta-tion in essential thrombocythemia", Leukemia, 19, pp.1847~1849 (2005)[DOI]
6. Jing Wang, "JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia", Hematology, 22(3), pp.145~148 (2016), Informa UK Limited[DOI]
7. 김보현, "JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis", Journal of Korean Medical Science, 30(7), pp.882~888 (2015), 대한의학회
8. Kim SY, "CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable", Am J Clin Pathol, 143, pp.635~644 (2015)[DOI]
9. Lin Y, "The prevalence of JAK2, MPL, and CALR mutations in Chinese patients with BCR-ABL1-negative myeloproliferative neoplasms", Am J Clin Pathol, 144, pp.165~171 (2015)[DOI]
10. Lang T, "Correlation analysis between JAK2, MPL, and CALR mutations in patients with myeloproliferative neoplasms of Chinese Uygur and Han na-tionality and their clinical characteristics", J Int Med Res, 46, pp.4650~4659 (2018)[DOI]
11. Klampfl T, "Somatic mutations of calreticulin in myelo-proliferative neoplasms", N Engl J Med, 369, pp.2379~2390 (2013)[DOI]
12. William Vainchenker, "Recent advances in understanding myelofibrosis and essential thrombocythemia", F1000Research, 5, pp.700~ (2016), F1000 Research Ltd[DOI]
13. Ji L, "Significance of combined detection of JAK2V617F, MPL and CALR gene mutations in patients with es-sential thrombocythemia", Exp Ther Med, 13, pp.947~951 (2017)[DOI]
14. Wu Z, "The mutation profile of JAK2 and CALR in Chinese Han patients with Philadel-phia chromosome-negative myeloproliferative neoplasms", J Hematol Oncol, 7, pp.1~10 (2014)
15. Kim HR, "Allelic expression imbalance of JAK2 V617F mutation in BCR-ABL neg-ative myeloproliferative neoplasms", PLoS ONE, 8, pp.e52518~ (2013)[DOI]
16. Ojeda MJ, "CALR, JAK2 and MPL mutation status in argentinean patients with BCR-ABL1-negative myeloproliferative neoplasms", Hematology, 23, pp.208~211 (2018)[DOI]
17. Syeed N, "JAK2 and Beyond : JAK2V617 mutational study of myelo-proliferative disorders and haematological malignancies", Asian Pac J Cancer Prev, 20, pp.3611~3615 (2019)[DOI]
18. Jaradat SA, "Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms", Hematol Oncol Stem Cell Ther, 8, pp.160~166 (2015)[DOI]
19. Nancy LM, "The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms", Hematol Oncol Stem Cell Ther, 8, pp.16~21 (2015)[DOI]
20. Vu HA, "Clinical and hematological relevance of JAK2V617F, CALR, and MPL mutations in Vietnamese patients with essential thrombocythemia", Asian Pac J Cancer Prev, 20, pp.2775~2780 (2019)[DOI]
21. Li MY, "Clinical significance of JAK2, CALR, and MPL gene mutations in 1648Philadelphia chromosome negative myeloproliferative neo-plasms patients from a single center", chinese Journal of Hematology, 38, pp.295~300 (2017)[DOI]
22. Misawa K, "Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms", Int J Hematol, 107, pp.673~680 (2018)[DOI]
23. Ayfer Geduk, "The Role of β-Catenin in Bcr", Abl Negative Myeloproliferative Neoplasms: An Immunohistochemical Study, 2015, pp.15(12), 785~789[DOI]
24. Gardner JA, "Detection of CALR mutation in clonal and non clonal hematologic diseases using fragment analysis and next-generation sequencing", Am J Clin Pathol, 146, pp.448~455 (2016)[DOI]
25. Lussana F, "Driver mutations(JAK2V617F, MPLW515L", K or CALR), pentraxin-3 and C-reactive protein in essential throm-bocythemia and polycythemia vera, 2017, pp.10, 2~8
26. Xu W, "MPL W515L muta-tion in Chinese patients with myeloproliferative diseases", Leuk Lymphoma, 49, pp.955~958 (2008)[DOI]
27. Chen X, "Detection of MPL exon10 mutations in 103 Chinese patients with JAK2V617F-neg-ative myeloproliferative neoplasms", Blood Cells Mol Dis, 47, pp.67~71 (2011)[DOI]
28. Toyama K, "Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr", abl-negative chronic myeloproli-ferative neoplasm subtypes, 2011, pp.50, 2557~2561
29. Smaili W, "CALR gene mutational profile in myeloproliferative neo-plasms with nonmutated JAK2 in Moroccan patients : a case series and germline in-frame deletion", Curr Res Transl Med, 65, pp.15~29 (2017)[DOI]
30. Schnittger S, "Molecular analyses of 15, 542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow", Haematologica, 97, pp.1582~1585 (2012)

관련 논문AI추천